Ascendis Pharma A/S (NASDAQ:ASND) Given New $113.00 Price Target at Morgan Stanley

Posted by Defense World Staff on Sep 7th, 2023

Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price upped by Morgan Stanley from $109.00 to $113.00 in a report issued on Wednesday morning, Benzinga reports. They currently have an equal weight rating on the biotechnology company’s stock.

A number of other research analysts have also recently issued reports on ASND. Wedbush lifted their price objective on Ascendis Pharma A/S from $187.00 to $192.00 and gave the company an outperform rating in a report on Wednesday. Wells Fargo & Company cut their price objective on Ascendis Pharma A/S from $139.00 to $134.00 and set an overweight rating for the company in a report on Wednesday. Finally, StockNews.com cut Ascendis Pharma A/S from a hold rating to a sell rating in a report on Wednesday, August 16th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $143.10.

Get Our Latest Stock Report on ASND

Ascendis Pharma A/S Stock Up 4.2 %

ASND opened at $103.97 on Wednesday. The company has a market capitalization of $5.96 billion, a P/E ratio of -9.91 and a beta of 0.50. The firm’s fifty day moving average price is $91.78 and its two-hundred day moving average price is $93.51. Ascendis Pharma A/S has a fifty-two week low of $64.33 and a fifty-two week high of $134.52. The company has a debt-to-equity ratio of 2.87, a current ratio of 4.08 and a quick ratio of 3.32.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Avoro Capital Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 8.8% in the fourth quarter. Avoro Capital Advisors LLC now owns 3,100,000 shares of the biotechnology company’s stock valued at $378,603,000 after buying an additional 250,000 shares during the last quarter. Tamarack Advisers LP increased its position in Ascendis Pharma A/S by 200.0% in the fourth quarter. Tamarack Advisers LP now owns 45,000 shares of the biotechnology company’s stock worth $5,496,000 after purchasing an additional 30,000 shares during the period. First Republic Investment Management Inc. increased its position in Ascendis Pharma A/S by 682.2% in the fourth quarter. First Republic Investment Management Inc. now owns 117,323 shares of the biotechnology company’s stock worth $14,329,000 after purchasing an additional 102,323 shares during the period. Finepoint Capital LP increased its position in Ascendis Pharma A/S by 16.4% in the first quarter. Finepoint Capital LP now owns 156,072 shares of the biotechnology company’s stock worth $16,734,000 after purchasing an additional 22,036 shares during the period. Finally, TimesSquare Capital Management LLC increased its position in Ascendis Pharma A/S by 23.7% in the fourth quarter. TimesSquare Capital Management LLC now owns 791,245 shares of the biotechnology company’s stock worth $96,635,000 after purchasing an additional 151,570 shares during the period.

Ascendis Pharma A/S Company Profile

(Get Free Report)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia.